Rheumatoid arthritis microenvironment insights into treatment effect of nanomaterials
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Extracellular vesicles in disease · Immune cells in cancer · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis10.1038/s41584-018-0109-2 ↗
2. Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis10.1038/s41584-019-0187-9 ↗
3. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 201710.1016/S0140-6736(18)32203-7 ↗
4. Lung inflammation in the pathogenesis of rheumatoid arthritis10.1111/imr.12842 ↗
5. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality10.1136/annrheumdis-2017-211138 ↗
6. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis10.1038/s41584-020-0428-y ↗
7. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort10.1136/annrheumdis-2017-211209 ↗
8. Diagnosis and management of rheumatoid arthritis: a review10.1001/jama.2018.13103 ↗
9. Novel treatment strategies in rheumatoid arthritis10.1016/S0140-6736(17)31491-5 ↗
10. Rheumatoid arthritis10.1038/nrdp.2018.1 ↗
11. Location, location, location: how the tissue microenvironment affects inflammation in RA10.1038/s41584-020-00570-2 ↗
12. Immunometabolism in early and late stages of rheumatoid arthritis10.1038/nrrheum.2017.49 ↗
13. ROS-responsive berberine polymeric micelles effectively suppressed the inflammation of rheumatoid arthritis by targeting mitochondria
14. The past, present and future perspectives of matrix metalloproteinase inhibitors10.1016/j.pharmthera.2019.107465 ↗
15. Oxidative stress in rheumatoid arthritis: what the future might hold regarding novel biomarkers and add-on therapies10.1155/2019/7536805 ↗
16. Rheumatoid arthritis10.7326/AITC201901010 ↗
17. Methotrexate and its mechanisms of action in inflammatory arthritis10.1038/s41584-020-0373-9 ↗
18. Why remission is not enough: underlying disease mechanisms in RA that prevent cure10.1038/s41584-020-00543-5 ↗
19. Nanomaterials for nanotheranostics: tuning their properties according to disease needs10.1021/acsnano.9b08133 ↗
20. Smart design of nanomaterials for mitochondria-targeted nanotherapeutics10.1002/anie.201915826 ↗
21. Nanoparticles’ interactions with vasculature in diseases10.1039/C9CS00309F ↗
22. Cationic block copolymer nanoparticles with tunable DNA affinity for treating rheumatoid arthritis10.1002/adfm.202000391 ↗
23. Nanoemulsions target to ectopic lymphoids in inflamed joints to restore immune tolerance in rheumatoid arthritis10.1021/acs.nanolett.0c05110 ↗
24. Advances in genetics toward identifying pathogenic cell states of rheumatoid arthritis10.1111/imr.12827 ↗
25. The arsenic-binding aptamer cannot bind arsenic: critical evaluation of aptamer selection and binding10.1021/acs.analchem.9b02789 ↗
26. Synergistic oxygen generation and reactive oxygen species scavenging by manganese ferrite/ceria co-decorated nanoparticles for rheumatoid arthritis treatment10.1021/acsnano.8b08785 ↗
27. Insights into the study and origin of the citrullinome in rheumatoid arthritis10.1111/imr.12834 ↗
28. The influence of ACPA status and characteristics on the course of RA10.1038/nrrheum.2011.204 ↗
29. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases10.3389/fphys.2020.578966 ↗
30. Cell-free DNA as a biomarker in autoimmune rheumatic diseases10.3389/fimmu.2019.00502 ↗
31. Polymeric aggregate-embodied hybrid nitric-oxide-scavenging and sequential drug-releasing hydrogel for combinatorial treatment of rheumatoid arthritis10.1002/adma.202008793 ↗
32. Autoantibodies and B cells: the ABC of rheumatoid arthritis pathophysiology10.1111/imr.12829 ↗
33. ROS-scavenging nanomaterials to treat periodontitis10.3389/fchem.2020.595530 ↗
34. Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation10.1038/s41467-021-21242-z ↗
35. Notch signalling drives synovial fibroblast identity and arthritis pathology10.1038/s41586-020-2222-z ↗
36. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes10.1038/s41584-020-0413-5 ↗
37. Ectopic lymphoid organs and immune-mediated diseases: molecular basis for pharmacological approaches10.1016/j.molmed.2020.06.004 ↗
38. Targeting CD34(+) cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis10.1016/j.jaut.2019.05.016 ↗
39. Microvascular endothelial dysfunction in rheumatoid arthritis10.1038/s41584-018-0022-8 ↗
40. Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis10.1038/s41467-021-22454-z ↗
41. Simultaneous fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy10.1002/anie.201712027 ↗
42. HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis10.1038/s41467-019-12163-z ↗
43. Interleukin-17 in rheumatoid arthritis: trials and tribulations10.1084/jem.20192048 ↗
44. The pathogenesis of rheumatoid arthritis10.1056/NEJMra1004965 ↗
45. The role of autoantibodies in the pathophysiology of rheumatoid arthritis10.1007/s00281-017-0627-z ↗
46. Neutrophils in rheumatoid arthritis: breaking immune tolerance and fueling disease10.1016/j.molmed.2018.12.008 ↗
47. Nox/Duox family of NADPH oxidases: lessons from knockout mouse models10.1016/j.tips.2016.01.006 ↗
48. Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries
49. Neutrophils and redox stress in the pathogenesis of autoimmune disease10.1016/j.freeradbiomed.2018.03.049 ↗
50. Reactive oxygen species (ROS)-based nanomedicine10.1021/acs.chemrev.8b00626 ↗
51. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis10.1038/nrrheum.2016.69 ↗
52. Oxidative stress in autoimmune rheumatic diseases10.1016/j.freeradbiomed.2018.05.086 ↗
53. Inflammaging and oxidative stress in human diseases: from molecular mechanisms to novel treatments10.3390/ijms20184472 ↗
54. 30 years of NF-kappaB: a blossoming of relevance to human pathobiology10.1016/j.cell.2016.12.012 ↗
55. Nanotherapies for sepsis by regulating inflammatory signals and reactive oxygen and nitrogen species: new insight for treating COVID-1910.1016/j.redox.2021.102046 ↗
56. Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review10.1016/j.autrev.2019.102397 ↗
57. Oxidative stress and lipid mediators modulate immune cell functions in autoimmune diseases10.3390/ijms22020723 ↗
58. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis10.1038/s41584-018-0109-2 ↗
59. Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis10.1016/j.cbi.2017.12.024 ↗
60. Oxidative stress and lipid mediators modulate immune cell functions in autoimmune diseases10.3390/ijms22020723 ↗
61. Synovial tissue research: a state-of-the-art review10.1038/nrrheum.2017.115 ↗
62. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis10.1111/j.0105-2896.2009.00859.x ↗
63. ROS and ROS-mediated cellular signaling10.1155/2016/4350965 ↗
64. Apoptosis induction of fibroblast-like synoviocytes is an important molecular-mechanism for herbal medicine along with its active components in treating rheumatoid arthritis10.3390/biom9120795 ↗
65. Cellular and molecular perspectives in rheumatoid arthritis10.1007/s00281-017-0633-1 ↗
66. The pathogenic role of angiogenesis in rheumatoid arthritis10.1007/s10456-015-9477-2 ↗
67. Cross-talk between NADPH oxidase and mitochondria: role in ROS signaling and angiogenesis10.3390/cells9081849 ↗
68. Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis10.1186/s13075-018-1592-1 ↗
69. HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1alpha activation10.1002/eji.201444908 ↗
70. Targeting synovial neoangiogenesis in rheumatoid arthritis10.1016/j.autrev.2017.04.005 ↗
71. Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate10.1002/jcb.25074 ↗
72. Relationship between PI3K pathway and angiogenesis in CIA rat synovium
73. Cartilage damage in osteoarthritis and rheumatoid arthritis--two unequal siblings10.1038/nrrheum.2015.95 ↗
74. Mediators of inflammation and bone remodeling in rheumatic disease10.1016/j.semcdb.2015.10.013 ↗
75. Consequences of metabolic and oxidative modifications of cartilage tissue10.1038/nrrheum.2015.70 ↗
76. Advanced oxidation protein products induce chondrocyte apoptosis via receptor for advanced glycation end products-mediated, redox-dependent intrinsic apoptosis pathway10.1007/s10495-015-1191-4 ↗
77. Neutrophil-derived mitochondrial DNA promotes receptor activator of nuclear factor kappaB and its ligand signalling in rheumatoid arthritis10.1093/rheumatology/kex041 ↗
78. Mechanisms involved in normal and pathological osteoclastogenesis10.1007/s00018-018-2817-9 ↗
79. Cartilage and bone destruction in arthritis: pathogenesis and treatment strategy: a literature review10.3390/cells8080818 ↗
80. Molecular regulatory mechanisms of osteoclastogenesis through cytoprotective enzymes10.1016/j.redox.2016.01.006 ↗
81. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents10.1016/j.autrev.2019.102398 ↗
82. Novel therapeutic targets in rheumatoid arthritis10.1016/j.tips.2015.02.001 ↗
83. The problem of choice: current biologic agents and future prospects in RA10.1038/nrrheum.2013.8 ↗
84. Palmitic acid-modified bovine serum albumin nanoparticles target scavenger receptor-A on activated macrophages to treat rheumatoid arthritis10.1016/j.biomaterials.2020.120296 ↗
85. Nitric oxide-scavenging nanogel for treating rheumatoid arthritis10.1021/acs.nanolett.9b00496 ↗
86. Endogenous inspired biomineral-installed hyaluronan nanoparticles as pH-responsive carrier of methotrexate for rheumatoid arthritis10.1016/j.jconrel.2017.03.012 ↗
87. Enhanced therapeutic effect of RGD-modified polymeric micelles loaded with low-dose methotrexate and nimesulide on rheumatoid arthritis10.7150/thno.30418 ↗
88. Intra-articular targeting of nanomaterials for the treatment of osteoarthritis10.1016/j.actbio.2019.03.010 ↗
89. Nano based drug delivery systems: recent developments and future prospects10.1186/s12951-018-0392-8 ↗
90. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy10.7150/thno.49577 ↗
91. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?10.1016/j.jconrel.2016.11.015 ↗
92. Platelets can enhance vascular permeability10.1182/blood-2012-02-413047 ↗
93. Hyaluronate-functionalized hydroxyapatite nanoparticles laden with methotrexate and teriflunomide for the treatment of rheumatoid arthritis10.1016/j.ijbiomac.2020.12.204 ↗
94. Self-powered intracellular drug delivery by a biomechanical energy-driven triboelectric nanogenerator10.1002/adma.201807795 ↗
95. Nitrite-responsive hydrogel: smart drug release depending on the severity of the nitric oxide-related disease10.1021/acsami.0c13688 ↗
96. Self-assembled pH-sensitive polymeric nanoparticles for the inflammation-targeted delivery of Cu/Zn-superoxide dismutase10.1021/acsami.1c03589 ↗
97. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe10.1002/art.30628 ↗
98. Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis10.1016/j.biomaterials.2017.03.044 ↗
99. A core-shell structure QRu-PLGA-RES-DS NP nanocomposite with photothermal response-induced M2 macrophage polarization for rheumatoid arthritis therapy10.1039/C9NR05922A ↗
100. Macrophage plasticity, polarization, and function in health and disease10.1002/jcp.26429 ↗